Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Multicentre, Phase III Study in Patients With Intermediate-risk T1 T2 Prostate Adenocarcinomas, to Verify the Role of Six Months of Total Androgen Blockade for Two Dosage Levels of Prostate Radiation Therapy (70 Gy and 76 Gy) Versus Prostate Radiation Therapy Alone at 76 Gy

NCT00223145 is registered in ClinicalTrials.gov with Abdenour Nabid as lead sponsor.

NCT NCT00223145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00223145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Multicentre, Phase III Study in Patients With Intermediate-risk T1 T2 Prostate Adenocarcinomas, to Verify the Role of Six Months of Total Androgen Blockade for Two Dosage Levels of Prostate Radiation Therapy (70 Gy and 76 Gy) Versus Prostate Radiation Therapy Alone at 76 Gy
Lead sponsor
Abdenour Nabid
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 31, 2000
Completion date
December 31, 2027
Enrollment
600 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer